Drug intelligence / Profile preview

Lefukang Capsule (Chongqing Searainbow Pharmaceutical)

Development stage: Unknown
Lead developer: Chongqing Searainbow Pharmaceutical
Administration: Oral

Overview

Lefukang Capsule is a Traditional Chinese Medicine (TCM) developed by Chongqing Searainbow Pharmaceutical for the treatment of chronic pelvic pain resulting from the sequelae of pelvic inflammatory disease (PID). It is specifically indicated for patients presenting with the TCM pattern of qi stagnation and blood stasis. The formulation aims to promote blood circulation, resolve stasis, and alleviate pain. It has been evaluated in a randomized, double-blind Phase 3 clinical trial in China, comparing its efficacy and safety against Kunfukang Capsule, another TCM product used for similar indications.

Brand names: Lefukang Capsule
Other names: Lefukang乐妇康胶囊

Beyond the preview

Go deeper on Lefukang Capsule (Chongqing Searainbow Pharmaceutical).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lefukang Capsule (Chongqing Searainbow Pharmaceutical).

Explore the full profile